NZ702415A - Methods for treating neutropenia using retinoid agonists - Google Patents

Methods for treating neutropenia using retinoid agonists

Info

Publication number
NZ702415A
NZ702415A NZ702415A NZ70241513A NZ702415A NZ 702415 A NZ702415 A NZ 702415A NZ 702415 A NZ702415 A NZ 702415A NZ 70241513 A NZ70241513 A NZ 70241513A NZ 702415 A NZ702415 A NZ 702415A
Authority
NZ
New Zealand
Prior art keywords
methods
treating neutropenia
neutropenia
retinoid agonists
subject
Prior art date
Application number
NZ702415A
Other languages
English (en)
Inventor
Lingtao Wu
Original Assignee
Children’S Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children’S Hospital Los Angeles filed Critical Children’S Hospital Los Angeles
Publication of NZ702415A publication Critical patent/NZ702415A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ702415A 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists NZ702415A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (1)

Publication Number Publication Date
NZ702415A true NZ702415A (en) 2016-04-29

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ702415A NZ702415A (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Country Status (13)

Country Link
US (1) US11116738B2 (enExample)
EP (1) EP2858636B1 (enExample)
JP (1) JP6295249B2 (enExample)
KR (1) KR102083046B1 (enExample)
CN (1) CN104519879B (enExample)
AU (1) AU2013270674B2 (enExample)
BR (1) BR112014030279A2 (enExample)
CA (1) CA2874850A1 (enExample)
ES (1) ES2691493T3 (enExample)
MX (1) MX365321B (enExample)
NZ (1) NZ702415A (enExample)
RU (1) RU2650962C2 (enExample)
WO (1) WO2013185105A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2858636B1 (en) 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
EP2969031A4 (en) 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topical compositions for reducing aging effects
EP3277272B1 (en) * 2015-03-31 2021-08-04 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-agonists
KR20240157122A (ko) 2016-04-08 2024-10-31 사이로스 파마수티컬스, 인크. Aml 및 mds 치료용 rara 효능제
TW201823471A (zh) * 2016-10-06 2018-07-01 美商錫羅斯製藥公司 以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法
US20210123021A1 (en) * 2018-01-26 2021-04-29 Agency For Science, Technology And Research Neutrophil subtypes
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY
WO2025250787A2 (en) * 2024-05-30 2025-12-04 The Children's Medical Center Corporation Compositions and methods for treating sepsis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
CA2273288A1 (en) * 1996-12-19 1998-06-25 James Joseph Gibbons Method of treating or inhibiting neutropenia
AU9084601A (en) 2000-09-08 2002-03-22 Massachusetts Inst Technology G-csf analog compositions and methods
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2004100972A1 (ja) 2003-05-16 2004-11-25 Kyowa Hakko Kogyo Co., Ltd. 組織破壊を伴う疾患の予防及び／または治療剤
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
RS51506B (sr) 2004-12-02 2011-06-30 Venus Remedies Limited H. O&R&D. Smeše za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
CN101472572B (zh) 2006-05-16 2012-10-10 Io治疗有限责任公司 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
MX2009009997A (es) * 2007-03-30 2009-12-08 Tmrc Co Ltd Preparacion de la capsula de tamibarotene.
JP2011505386A (ja) * 2007-12-06 2011-02-24 シーエスエル、リミテッド 白血病性幹細胞の阻害方法
US8580516B2 (en) 2008-09-05 2013-11-12 University Of Chicago Methods and compositions for direct detection of DNA damage
AU2010309388B2 (en) 2009-10-19 2016-03-10 Laila Nutraceuticals Extracts, fractions and compositions comprising acetogenins and their applications
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
EP2847198B1 (en) * 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
EP2858636B1 (en) 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Also Published As

Publication number Publication date
RU2650962C2 (ru) 2018-04-18
ES2691493T3 (es) 2018-11-27
BR112014030279A2 (pt) 2017-09-12
EP2858636A4 (en) 2016-06-01
MX2014014930A (es) 2015-07-06
KR20150035983A (ko) 2015-04-07
US20150164836A1 (en) 2015-06-18
RU2014153988A (ru) 2016-07-27
JP6295249B2 (ja) 2018-03-14
MX365321B (es) 2019-05-29
EP2858636B1 (en) 2018-09-05
CA2874850A1 (en) 2013-12-12
AU2013270674B2 (en) 2017-12-07
AU2013270674A1 (en) 2014-12-18
CN104519879A (zh) 2015-04-15
WO2013185105A1 (en) 2013-12-12
KR102083046B1 (ko) 2020-02-28
HK1208630A1 (en) 2016-03-11
CN104519879B (zh) 2018-10-02
JP2015523346A (ja) 2015-08-13
EP2858636A1 (en) 2015-04-15
US11116738B2 (en) 2021-09-14

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
MX2016007965A (es) Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MA39817A (fr) Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
MX383893B (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX2014007169A (es) Tratamiento de trastorno autoinmune al usar agonistas de rxr.
IL239921A0 (en) Preparations containing solutions in solid state and their use for the treatment of pain
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
NZ704496A (en) Retinoids and use thereof
PH12020552048A1 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
EP3581205A3 (en) Product and method for treating diarrhea
MX2016001104A (es) Composiciones para tratar engrosamiento de la piel.
WO2014146111A3 (en) Analgesic compounds and methods of use
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX394633B (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamina (nmda)
BR112016012248A2 (pt) método de tratamento de nefropatia
MX2013013182A (es) Tratamiento de la mastitis.
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
MX386151B (es) Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20170518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JUN 2020 BY COMPUTER PACKAGES INC

Effective date: 20190518

LAPS Patent lapsed